At a glance
ClinicalIndex Comparison RecordN/ACompleted· 60 enrolled
Drug / intervention
Active tDCSdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Intra-Individual Variability in Cognitive Performance as a Marker of Prodromal Disability in MS
In Brief
A clinical study evaluating Active tDCS for Multiple Sclerosis. Completed, enrolled 60 participants across 1 site.
Detailed Summary
The focus of this work is the evaluation of a measure of cognitive functioning- intra-individual variability (IIV) - derived from a computer-based continuous reaction time (RT) task (Cogstate) as an early marker of prodromal MS.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
CountriesUnited States
CollaboratorsNational Multiple Sclerosis Society
Timeline
N/ACompletedFinished
20222023202420252026
Enrollment StartFeb 2022
First PostedSep 2022
Primary CompletionJun 2024
TodayJul 2026
First PostedSep 16, 2022
Enrollment StartFeb 9, 2022
Primary CompletionJun 20, 2024
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 3.8 years ago
Interventions
Active tDCSdevice
The tDCS-MRI scan will last approximately one hour. The first 20 minutes of the MRI will not include tDCS stimulation. After 20 minutes, the tDCS device will ramp up to 2.0mA and deliver 2.0mA for 20 minutes. Then the tDCS will ramp down (30 seconds) and the final 20 minutes will be without stimulation.